The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 2.5% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 29% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 137%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (11 analysts) rates it buy, with a mean price target of $5563.
Ebara Corporation
6361.T · JPX · USD · Market cap $1.97T
Ebara Corporation manufactures and sells pumps, compressors, turbines, and chillers in Europe, the Middle East, Africa, Asia, Japan, Oceania, North America, and Central and South America.
PASS · Titan EthicalScreen close, 2026-09-23 · not a live quote
Last reviewed 13 days ago
Screened 2026-09-23 · the tape above runs as of 11:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
What this means: price 4,323.00 against the desk's fair-value range, base estimate 4,183.80, over the last year.
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Ebara Corporation holds its Markup at $4,323.00. Consolidating, no directional conviction, held for 21 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 21 days |
| Price at the screen | $4,323.00 |
| Valuation | 25.12 trailing · 28.28 forward price to earnings |
| Values screen | PASS |
| Beta | 1.20 |
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 20.77% | Below 33% | Interest-bearing debt is just 20.8% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.47% | Below 33% | Cash held in interest-bearing accounts and securities is 0.5% of assets, under the one-third limit. | Pass |
| Receivables | 32.59% | Below 49% | Money owed to the company is 32.6% of assets, under the 49% limit. | Pass |
| Revenue purity | 0.30% | Below 5% | Only 0.3% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Clears, in Plain English
Ebara clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 21%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
What the Numbers Say It Is WorthThe Fair Value Range
Fair value range in USD, drawn from the 2026-09-23 screen. The gold marker is the market price at the same screen. The price runs 3.2% above the base estimate.
Third-party analyst targets: 11 covering, consensus Buy. The average target sits +57% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | 28.3xexpensive even after accounting for its growth |
| Trailing P/E | 25.1xa premium valuation |
| EPS, trailing | 172.06 |
| EPS, forward | 152.88 |
| Revenue growth | +3.5%slow but positive growth |
| Profit margin | 7.9%thin but positive margins |
| Return on equity | 15.7%a solid return on shareholder capital |
| FCF yield | -3.89% |
| Debt to equity | 0.42minimal debt: a conservative balance sheet |
| Current ratio | 1.80healthy short-term liquidity |
| Beta | 1.20moves a little more than the market |
| 52-week range | 3,089.00 - 6,890.00 |
| Moat | MODERATE |
| Market cap | $1.97T |
The risks · The things to watch: its business and earnings are exposed to Japan and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade6361.T trades on JPX (the company is based in Japan). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 16.9% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 29% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 137%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (11 analysts) rates it buy, with a mean price target of $5563.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.9% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 29% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 137%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (11 analysts) rates it buy, with a mean price target of $5563.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 29% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 137%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (11 analysts) rates it buy, with a mean price target of $5563.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 29% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 137%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (11 analysts) rates it buy, with a mean price target of $5563.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Rising Oil Prices, Bond Yields, AI Uncertainty Roil Asian Stock Markets MT Newswires · 8d ago
- Ebara (TSE:6361) Stock May Look Reasonable On Long Term Cash Flow Simply Wall St. · 14d ago
- Ebara (TSE:6361) Slides Despite Stronger Long Term Returns, Is The Stock Fully Valued? Simply Wall St. · 14d ago
- Tech Rout, China Economy, Fed Outlook Damp Asian Stock Markets MT Newswires · 14 Nov 2025
- Economic Reports, Looming US Government Shutdown Churn Asian Stock Markets MT Newswires · 30 Sep 2025
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $5,902.00 | -10.8% | · | $892 | -10.8% |
| 2 months | $5,124.00 | +2.8% | · | $1,028 | +2.8% |
| 3 months | $5,086.00 | +3.5% | · | $1,035 | +3.5% |
| 6 months | $3,904.72 | +34.8% | $31.00 | $1,356 | +35.6% |
| 1 year | $2,223.75 | +136.8% | $59.00 | $2,394 | +139.4% |
| 2 years | $2,256.83 | +133.3% | $114.00 | $2,383 | +138.3% |
| 3 years | $1,220.78 | +331.3% | $159.80 | $4,444 | +344.4% |
| 5 years | $926.87 | +468.0% | $231.00 | $5,930 | +493.0% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever 6361.T does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.